amylin glp-1 dual agonist Frontiers Amycretin vs Semaglutide: Next-Gen Dual
Description
Real-world effectiveness often differs from controlled trial results
TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-1)
Diabetes Care 39, 222230
01176-6/asset/8f252412-ab10-4527-8c33-9679c4f31f6c/main.assets/gr3_lrg.jpg)
According to FDA prescribing information, gastrointestinal adverse effects vary by medication and dose, typically occurring in 15-45% of patients, particularly during dose escalation
CagriSema combines cagrilintide (an amylin analog) with semaglutide
doi: 10.3390/molecules27134315
